HER2-targeted therapy shows promising results in rare bile duct cancers

Zanidatamab, a bispecific HER2-targeted antibody, delivered clinically meaningful and durable responses for patients with HER2-positive biliary tract cancer (BTC), according to final results from the HERIZON-BTC-01 clinical trial led by…

Continue Reading

News Source: medicalxpress.com